(NTLA) Intellia Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.551m USD | Total Return: 100.8% in 12m

In Vivo, Ex Vivo, CRISPR, CAR-T, Genome Editing
Total Rating 46
Safety 34
Buy Signal -0.38
Biotechnology
Industry Rotation: +3.6
Market Cap: 1.55B
Avg Turnover: 41.5M USD
ATR: 6.81%
Peers RS (IBD): 47.3
Risk 5d forecast
Volatility79.1%
Rel. Tail Risk-7.82%
Reward TTM
Sharpe Ratio1.08
Alpha67.03
Character TTM
Beta1.858
Beta Downside2.163
Drawdowns 3y
Max DD86.36%
CAGR/Max DD-0.33
EPS (Earnings per Share) EPS (Earnings per Share) of NTLA over the last years for every Quarter: "2021-03": -0.69, "2021-06": -1.01, "2021-09": -0.97, "2021-12": -1.09, "2022-03": -1.96, "2022-06": -1.33, "2022-09": -1.49, "2022-12": -1.4, "2023-03": -1.17, "2023-06": -1.4, "2023-09": -1.38, "2023-12": -1.46, "2024-03": -1.12, "2024-06": -1.52, "2024-09": -1.34, "2024-12": -1.27, "2025-03": -1.1, "2025-06": -0.98, "2025-09": -0.92, "2025-12": -0.83, "2026-03": 0,
EPS CAGR: 54.87%
EPS Trend: 67.7%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of NTLA over the last years for every Quarter: 2021-03: 6.445, 2021-06: 6.55, 2021-09: 7.204, 2021-12: 12.854, 2022-03: 11.252, 2022-06: 14.03, 2022-09: 13.266, 2022-12: 13.573, 2023-03: 12.606, 2023-06: 13.594, 2023-09: 11.992, 2023-12: -1.917, 2024-03: 28.935, 2024-06: 6.957, 2024-09: 9.111, 2024-12: 12.874, 2025-03: 16.627, 2025-06: 14.245, 2025-09: 13.782, 2025-12: 23.017, 2026-03: null,
Rev. CAGR: 21.03%
Rev. Trend: 8.6%
Last SUE: 1.03
Qual. Beats: 1
Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: NTLA Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage gene-editing firm headquartered in Cambridge, MA, that pursues curative genome-editing medicines. Its lead in-vivo pipeline includes NTLA-2001, now in a Phase 2 trial for transthyretin amyloidosis, where interim data showed an average ≈ 80 % reduction in serum TTR levels, and NTLA-2002, advancing through Phase 1/2 for hereditary angioedema. The company also develops proprietary engineered-cell programs targeting multiple cancers and autoimmune disorders, leveraging collaborations with AvenCell, Kyverna, ONK Therapeutics and ReCode.

As of the most recent Q4 2025 filing, Intellia reported cash and cash equivalents of $658 million, giving it a runway into 2027, while R&D spending rose 22 % YoY to $251 million, reflecting accelerated trial activity. The broader biotechnology sector is benefiting from a projected 15 % CAGR (2024-2030) in the gene-editing market, driven by expanding FDA pathways and increasing investor appetite for one-time-cure modalities.

For a deeper dive into Intellia’s valuation metrics and how they compare within the gene-editing space, consider exploring ValueRay’s analysis. 

Headlines to Watch Out For
  • Clinical trial results for NTLA-2001 impact stock volatility
  • Regulatory approval for gene editing therapies drives revenue
  • Collaboration milestones with partners provide funding
  • Research and development expenses affect profitability
Piotroski VR‑10 (Strict) 0.0
Net Income: -412.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.47 > 0.02 and ΔFCF/TA -17.23 > 1.0
NWC/Revenue: 626.3% < 20% (prev 914.0%; Δ -287.7% < -1%)
CFO/TA -0.47 > 3% & CFO -394.7m > Net Income -412.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.08 > 1.5 & < 3
Outstanding Shares: last quarter (108.4m) vs 12m ago 6.40% < -2%
Gross Margin: -25.55% > 18% (prev 0.82%; Δ -2.64k% > 0.5%)
Asset Turnover: 6.66% > 50% (prev 4.86%; Δ 1.80% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.50 (Total Current Assets 527.7m - Total Current Liabilities 103.9m) / Total Assets 842.1m
B: -3.08 (Retained Earnings -2.59b / Total Assets 842.1m)
C: -0.42 (EBIT TTM -427.9m / Avg Total Assets 1.02b)
D: -15.16 (Book Value of Equity -2.59b / Total Liabilities 170.7m)
Altman-Z'' Score: -25.48 = D
Beneish M -3.03
DSRI: 0.95 (Receivables 9.47m/8.52m, Revenue 67.7m/57.9m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.89 (AQ_t 0.23 / AQ_t-1 0.26)
SGI: 1.17 (Revenue 67.7m / 57.9m)
TATA: -0.02 (NI -412.7m - CFO -394.7m) / TA 842.1m)
Beneish M-Score: -3.03 (Cap -4..+1) = AA
What is the price of NTLA shares? As of April 06, 2026, the stock is trading at USD 13.13 with a total of 2,750,500 shares traded.
Over the past week, the price has changed by +12.70%, over one month by -0.15%, over three months by +40.13% and over the past year by +100.76%.
Is NTLA a buy, sell or hold? Intellia Therapeutics has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy NTLA.
  • StrongBuy: 18
  • Buy: 4
  • Hold: 6
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the NTLA price?
Analysts Target Price 25.3 92.6%
Intellia Therapeutics (NTLA) - Fundamental Data Overview as of 04 April 2026
P/S = 22.9211
P/B = 2.334
P/EG = -0.0969
Revenue TTM = 67.7m USD
EBIT TTM = -427.9m USD
EBITDA TTM = -417.6m USD
Long Term Debt = 93.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 26.5m USD (from shortTermDebt, last quarter)
Debt = 93.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -62.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.19b USD (1.55b + Debt 93.3m - CCE 449.9m)
 Interest Coverage Ratio = unknown (Ebit TTM -427.9m / Interest Expense TTM 0.0)
 EV/FCF = -3.02x (Enterprise Value 1.19b / FCF TTM -395.9m)
FCF Yield = -33.14% (FCF TTM -395.9m / Enterprise Value 1.19b)
 FCF Margin = -585.0% (FCF TTM -395.9m / Revenue TTM 67.7m)
 Net Margin = -609.9% (Net Income TTM -412.7m / Revenue TTM 67.7m)
 Gross Margin = -25.55% ((Revenue TTM 67.7m - Cost of Revenue TTM 85.0m) / Revenue TTM)
Gross Margin QoQ = 73.87% (prev none%)
Tobins Q-Ratio = 1.42 (Enterprise Value 1.19b / Total Assets 842.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 93.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -338.1m (EBIT -427.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.08 (Total Current Assets 527.7m / Total Current Liabilities 103.9m)
Debt / Equity = 0.14 (Debt 93.3m / totalStockholderEquity, last quarter 671.4m)
 Debt / EBITDA = 0.15 (negative EBITDA) (Net Debt -62.1m / EBITDA -417.6m)
 Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -62.1m / FCF TTM -395.9m)
 Total Stockholder Equity = 728.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.60% (Net Income -412.7m / Total Assets 842.1m)
RoE = -56.63% (Net Income TTM -412.7m / Total Stockholder Equity 728.7m)
RoCE = -52.05% (EBIT -427.9m / Capital Employed (Equity 728.7m + L.T.Debt 93.3m))
 RoIC = -46.39% (negative operating profit) (NOPAT -338.1m / Invested Capital 728.7m)
 WACC = 11.81% (E(1.55b)/V(1.64b) * Re(12.52%) + D(93.3m)/V(1.64b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.46%
 [DCF] Fair Price = unknown (Cash Flow -395.9m)
 EPS Correlation: 67.69 | EPS CAGR: 54.87% | SUE: 4.0 | # QB: 1
Revenue Correlation: 8.65 | Revenue CAGR: 21.03% | SUE: 1.03 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-0.90 | Chg7d=+0.109 | Chg30d=+0.109 | Revisions Net=+4 | Analysts=15
EPS current Year (2026-12-31): EPS=-3.56 | Chg7d=+0.000 | Chg30d=+0.048 | Revisions Net=+2 | Growth EPS=+6.7% | Growth Revenue=-12.0%
EPS next Year (2027-12-31): EPS=-2.92 | Chg7d=+0.000 | Chg30d=-1.362 | Revisions Net=+3 | Growth EPS=+17.8% | Growth Revenue=+302.8%
[Analyst] Revisions Ratio: +0.50 (6 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle